Glypican-3 is positive in 65–80% of HCCs, more often in poorly differentiated than well differentiated tumors; however, glypican-3 may also be positive in a variety of other malignancies, such as carcinomas from other sites, melanoma, and germ cell tumors [70]. This evidence concerns the gene GPC3 and testicular germ cell tumor.